Cancer Immunotherapy Exam questions and
answers
Trastuzumab - ✅✅mab, HER2/ErbB2, humanized
Pertuzumab - ✅✅mab, HER2/ErbB2 (inh dimerization), humanized
cetuximab - ✅✅mab, EGFR, chimeric
Bevacizumab - ✅✅mab, VEGF (ligand), humanized
ramucirumab - ✅✅mab, VEGF (receptor), fully human
rituximab - ✅✅mab, CD20 (B cells), chimeric
daratumumab - ✅✅mab, CD38 (plasma cells), fully human
ipilimumab - ✅✅mab (checkpoint inh), CTLA-4 R, fully human
pembrolizumab - ✅✅mab (checkpoint inh), PD-1 (receptor), humanized
atezolizumab - ✅✅mab (checkpoint inh), PD-L1 (ligand), humanized
trastuzumab emtansine - ✅✅ADC, HER2 + microtubule assembly
trastuzumab deruxtecan - ✅✅HER2 + TopoI inh.or
blinotumomab - ✅✅BiTE, CD19 (B cell, ALL)
answers
Trastuzumab - ✅✅mab, HER2/ErbB2, humanized
Pertuzumab - ✅✅mab, HER2/ErbB2 (inh dimerization), humanized
cetuximab - ✅✅mab, EGFR, chimeric
Bevacizumab - ✅✅mab, VEGF (ligand), humanized
ramucirumab - ✅✅mab, VEGF (receptor), fully human
rituximab - ✅✅mab, CD20 (B cells), chimeric
daratumumab - ✅✅mab, CD38 (plasma cells), fully human
ipilimumab - ✅✅mab (checkpoint inh), CTLA-4 R, fully human
pembrolizumab - ✅✅mab (checkpoint inh), PD-1 (receptor), humanized
atezolizumab - ✅✅mab (checkpoint inh), PD-L1 (ligand), humanized
trastuzumab emtansine - ✅✅ADC, HER2 + microtubule assembly
trastuzumab deruxtecan - ✅✅HER2 + TopoI inh.or
blinotumomab - ✅✅BiTE, CD19 (B cell, ALL)